SODIUM BICARBONATE INJECTION, USP 42 MG — DIN 02486628
SODIUM BICARBONATE : 42 MG · FRESENIUS KABI CANADA LTD · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is SODIUM BICARBONATE INJECTION, USP?
SODIUM BICARBONATE INJECTION, USP 42 MG contains SODIUM BICARBONATE : 42 MG. It is listed in the Health Canada Drug Product Database under DIN 02486628, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 01-May-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is SODIUM BICARBONATE INJECTION, USP used for?
Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate is also indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Sodium Bicarbonate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Sodium Bicarbonate, across 18 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 3 | 1 | SODIUM BICARBONATE INJECTION USP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 2 | 1 | SODIUM BICARBONATE INJECTION, USP | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | SODIUM BICARBONATE INJECTION USP | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 1 | 1 | SODIUM BICARBONATE INJECTION USP | Sourceable in Canada |
| STERIMAX INC | 1 | 1 | SODIUM BICARBONATE INJECTION USP | Sourceable in Canada |
| INTERNATIONAL MEDICATION SYSTEMS LTD. | 3 | 0 | SODIUM BICARBONATE INJ 4.2%, SODIUM BICARBONATE INJ 7.5%, SODIUM BICARBONATE INJ 8.4% | No marketed DIN |
| ASTRAZENECA CANADA INC | 2 | 0 | SODIUM BICARBONATE INJECTION 75MG/ML, SODIUM BICARBONATE INJECTION 84MG/ML | No marketed DIN |
| PHEBRA CANADA INC | 2 | 0 | SODIUM BICARBONATE INJECTION | No marketed DIN |
| BAXTER CORPORATION | 1 | 0 | SODIUM BICARBONATE 5% INJ 5GM/100ML USP | No marketed DIN |
| JUNO PHARMACEUTICALS CORP. | 1 | 0 | SODIUM BICARBONATE INJECTION, USP | No marketed DIN |
| MCGAW INC. | 1 | 0 | SODIUM BICARBONATE 5% INJ 50MG/ML USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 42 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 10 mL Type I glass vial with a latex free stopper and an aluminium seal (for 4.2%); 50 mL Type I glass vial with a latex free stopper and an aluminium seal (for 8.4%) - both in trays of 25s |
| Storage | Store between 15°C and 30°C. Protect from freezing and avoid excessive heat. Note: brief exposure up to 40°C does not adversely affect the product. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Sodium Bicarbonate |
|---|---|
| ATC code | B05XA02 |
| AHFS class | 80:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02486628 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2486628 |
| Brand name | SODIUM BICARBONATE INJECTION, USP |
| Generic / active ingredient | SODIUM BICARBONATE : 42 MG |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Ethical |
| ATC code | B05XA02 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05XA |
| Current status | CANCELLED POST MARKET |
| Status date | 01-May-2025 |
| Original market date | 2020-03-27 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Sodium Bicarbonate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 18 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SODIUM BICARBONATE INJECTION USP | 84 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02467585 |
| SODIUM BICARBONATE INJECTION USP | 84 MG | SOLUTION | STERIMAX INC | MARKETED | 02541904 |
| SODIUM BICARBONATE INJECTION USP | 84 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 00261998 |
| SODIUM BICARBONATE INJECTION USP | 84 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02516225 |
| SODIUM BICARBONATE INJECTION, USP | 84 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02486636 |
| SODIUM BICARBONATE 5% INJ 50MG/ML USP | 50 MG | LIQUID | MCGAW INC. | CANCELLED POST MARKET | 01924214 |
| SODIUM BICARBONATE 5% INJ 5GM/100ML USP | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 00060445 |
| SODIUM BICARBONATE INJ 4.2% | 42 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00243914 |
| SODIUM BICARBONATE INJ 7.5% | 75 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00243922 |
| SODIUM BICARBONATE INJ 8.4% | 84 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00243930 |
2 · Same class — other molecules in ATC B05XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sodium Chloride | 0.45% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION · 0.9% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION, USP · +23 more | 37 | 11 | Yes |
| Potassium Chloride | POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE, USP (2 MEQ/ML) · POTASSIUM CHLORIDE INJ 149MG/ML USP · +7 more | 17 | 7 | Yes |
| Sodium Bicarbonate | SODIUM BICARBONATE 5% INJ 50MG/ML USP · SODIUM BICARBONATE 5% INJ 5GM/100ML USP · SODIUM BICARBONATE INJ 4.2% · SODIUM BICARBONATE INJ 7.5% · +6 more | 18 | 5 | Yes |
| Electrolytes In Comb With Other Drugs | ADDNUTRIV · MICRO +4 REGULAR STRENGTH · MICRO PLUS 4 CONCENTRATE · MICRO PLUS 5 CONCENTRATE · +10 more | 14 | 5 | Yes |
| Calcium Gluconate | 2% CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE INJECTION USP 10% · CALCIUM GLUCONATE INJECTION, USP 10% | 5 | 5 | Yes |
| Magnesium Sulphate | MAGNESIUM SULFATE IN WATER FOR INJECTION · MAGNESIUM SULFATE INJ 50% · MAGNESIUM SULFATE INJECTION 50% USP · MAGNESIUM SULFATE INJECTION BP · +3 more | 9 | 4 | Yes |
| Zinc Sulfate | MICRO ZN · ZINC SULFATE INJECTION, USP | 4 | 4 | Yes |
| Potassium Phos Incl Comb W/0th Pot. Salts | POTASSIUM PHOSPHATE INJ 3MMP/ML · POTASSIUM PHOSPHATE MONOBASIC INJECTION · POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATES INJ · +1 more | 5 | 3 | Yes |
| Calcium Chloride | CALCIJECT INJ 100MG/ML · CALCIUM CHLORIDE INJECTION BP · CALCIUM CHLORIDE INJECTION USP · CALCIUM-35 0.25 - 10 · +1 more | 5 | 2 | Yes |
| Sodium Acetate | 16.4% SODIUM ACETATE INJECTION, USP · SODIUM ACETATE INJ 328MG/ML USP · SODIUM ACETATE INJECTION USP · SODIUM ACETATE INJECTION, USP | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05XC | Vitamins | 9 | 2 |
| B05XX | Trometamol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.